Karachun Rita A 4

What Happened
Rita Karachun, a director of Coherus Oncology (CHRS), received equity awards on June 5, 2026: 30,000 restricted stock units (RSUs) and a 60,000-share derivative award (stock-option style). Both awards were granted at $0.00 (no cash paid) and are compensation/retention grants rather than open‑market purchases or sales.

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 9, 2026 (filed within the usual two-business-day window).
• Reported transaction type/code: A (Award/Grant). Reported acquisition price: $0.00; reported value $0.
• RSUs (30,000): Each RSU converts to one share upon vesting. Per footnote, 100% of these RSUs vest on the one‑year anniversary of June 3, 2026 (i.e., June 3, 2027), subject to Ms. Karachun’s continued service.
• Derivative award (60,000): Footnote indicates the underlying shares “vest and become exercisable” 100% on June 3, 2027, subject to continued service — i.e., a stock option–style award. No exercise price or immediate sale was disclosed.
• Shares owned after the transaction: not specified in the filing.
• No 10b5-1 plan, tax‑withholding sale, or other special arrangements were disclosed in the filing.

Context
RSUs and option-style derivative grants to directors are a common form of compensation and retention. RSUs convert to ordinary shares on the vesting date and typically trigger ordinary‑income tax for the recipient at vesting; options become exercisable per their terms. These awards do not represent an outlay by the insider now and are not sales — they reflect company compensation, not an immediate bullish or bearish trading signal.